(MIRM) Mirum Pharmaceuticals - Overview
Stock: Livmarli, Cholbam, Chenodal, Volixibat
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 45.3% |
| Relative Tail Risk | -10.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.76 |
| Alpha | 79.44 |
| Character TTM | |
|---|---|
| Beta | 0.749 |
| Beta Downside | 0.874 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.52% |
| CAGR/Max DD | 1.93 |
Description: MIRM Mirum Pharmaceuticals January 13, 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) is a U.S.-based biopharma that targets rare and orphan diseases, primarily through orally administered, minimally absorbed agents that inhibit the ileal bile acid transporter (IBAT). Its flagship product, LIVMARLI (maralixibat), received FDA approval for treating cholestatic pruritus in Alagille syndrome and is now marketed in the United States and several international jurisdictions.
Beyond LIVMARLI, Mirum commercializes Cholbam (cholic acid capsules) for bile-acid synthesis disorders and peroxisomal disorders, and Chenodal (tablet) for radiolucent gallbladder stones, which is also in a Phase 3 trial for cerebrotendinous xanthomatosis. The pipeline includes Volixibat, an IBAT inhibitor currently in a Phase 2b study for adult cholestatic liver diseases.
As of the latest 10-Q (Q3 2024), Mirum reported cash and cash equivalents of roughly $210 million, giving it an estimated 12-month runway at current burn rates. The company’s market capitalization hovers around $600 million, and its revenue is concentrated (>90%) in LIVMARLI sales, which grew ~45% YoY after its U.S. launch. The stock trades at a forward-PE of ~30×, reflecting investor expectations of pipeline expansion.
Sector-wide, rare-disease biotechs have benefited from higher pricing power and faster regulatory pathways, but they remain vulnerable to payer pushback and the need for robust post-approval data. For a deeper dive into Mirum’s valuation metrics and risk profile, a quick look at ValueRay’s analyst page can provide useful context without any sales spin.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -41.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 9.72 > 1.0 |
| NWC/Revenue: 78.47% < 20% (prev 88.22%; Δ -9.76% < -1%) |
| CFO/TA 0.06 > 3% & CFO 44.7m > Net Income -41.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.0m) vs 12m ago 19.28% < -2% |
| Gross Margin: 79.92% > 18% (prev 0.73%; Δ 7919 % > 0.5%) |
| Asset Turnover: 64.94% > 50% (prev 45.97%; Δ 18.97% > 0%) |
| Interest Coverage Ratio: -2.07 > 6 (EBITDA TTM -5.49m / Interest Expense TTM 14.4m) |
Altman Z'' -1.34
| A: 0.47 (Total Current Assets 530.6m - Total Current Liabilities 160.4m) / Total Assets 785.1m |
| B: -0.84 (Retained Earnings -661.8m / Total Assets 785.1m) |
| C: -0.04 (EBIT TTM -29.7m / Avg Total Assets 726.5m) |
| D: -1.34 (Book Value of Equity -661.8m / Total Liabilities 493.1m) |
| Altman-Z'' Score: -1.34 = CCC |
Beneish M -2.96
| DSRI: 1.02 (Receivables 107.1m/68.5m, Revenue 471.8m/307.0m) |
| GMI: 0.91 (GM 79.92% / 72.68%) |
| AQI: 0.77 (AQ_t 0.31 / AQ_t-1 0.41) |
| SGI: 1.54 (Revenue 471.8m / 307.0m) |
| TATA: -0.11 (NI -41.4m - CFO 44.7m) / TA 785.1m) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of MIRM shares?
Over the past week, the price has changed by -2.66%, over one month by +31.40%, over three months by +48.36% and over the past year by +96.12%.
Is MIRM a buy, sell or hold?
- StrongBuy: 6
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MIRM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 114.7 | 14.2% |
| Analysts Target Price | 114.7 | 14.2% |
| ValueRay Target Price | 164.1 | 63.3% |
MIRM Fundamental Data Overview February 02, 2026
P/S = 13.1007
P/B = 21.1023
Revenue TTM = 471.8m USD
EBIT TTM = -29.7m USD
EBITDA TTM = -5.49m USD
Long Term Debt = 309.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.04m USD (from shortTermDebt, last quarter)
Debt = 318.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 36.7m USD (from netDebt column, last quarter)
Enterprise Value = 6.12b USD (6.18b + Debt 318.8m - CCE 375.5m)
Interest Coverage Ratio = -2.07 (Ebit TTM -29.7m / Interest Expense TTM 14.4m)
EV/FCF = 138.2x (Enterprise Value 6.12b / FCF TTM 44.3m)
FCF Yield = 0.72% (FCF TTM 44.3m / Enterprise Value 6.12b)
FCF Margin = 9.39% (FCF TTM 44.3m / Revenue TTM 471.8m)
Net Margin = -8.78% (Net Income TTM -41.4m / Revenue TTM 471.8m)
Gross Margin = 79.92% ((Revenue TTM 471.8m - Cost of Revenue TTM 94.8m) / Revenue TTM)
Gross Margin QoQ = 80.80% (prev 81.67%)
Tobins Q-Ratio = 7.80 (Enterprise Value 6.12b / Total Assets 785.1m)
Interest Expense / Debt = 1.13% (Interest Expense 3.61m / Debt 318.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -23.5m (EBIT -29.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.31 (Total Current Assets 530.6m / Total Current Liabilities 160.4m)
Debt / Equity = 1.09 (Debt 318.8m / totalStockholderEquity, last quarter 292.0m)
Debt / EBITDA = -6.70 (negative EBITDA) (Net Debt 36.7m / EBITDA -5.49m)
Debt / FCF = 0.83 (Net Debt 36.7m / FCF TTM 44.3m)
Total Stockholder Equity = 251.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.70% (Net Income -41.4m / Total Assets 785.1m)
RoE = -16.47% (Net Income TTM -41.4m / Total Stockholder Equity 251.5m)
RoCE = -5.30% (EBIT -29.7m / Capital Employed (Equity 251.5m + L.T.Debt 309.4m))
RoIC = -4.19% (negative operating profit) (NOPAT -23.5m / Invested Capital 560.2m)
WACC = 8.29% (E(6.18b)/V(6.50b) * Re(8.67%) + D(318.8m)/V(6.50b) * Rd(1.13%) * (1-Tc(0.21)))
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.45%
[DCF Debug] Terminal Value 68.91% ; FCFF base≈44.3m ; Y1≈29.1m ; Y5≈13.3m
Fair Price DCF = 3.51 (EV 247.0m - Net Debt 36.7m = Equity 210.3m / Shares 59.9m; r=8.29% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 84.96 | EPS CAGR: 26.54% | SUE: 0.21 | # QB: 0
Revenue Correlation: 83.52 | Revenue CAGR: 171.6% | SUE: 0.36 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=+0.116 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=0.02 | Chg30d=+0.176 | Revisions Net=+0 | Growth EPS=+107.3% | Growth Revenue=+25.4%